IJRR

International Journal of Research and Review

| Home | Current Issue | Archive | Instructions to Authors | Journals |

Original Research Article

Year: 2020 | Month: April | Volume: 7 | Issue: 4 | Pages: 311-314

Drug Pentoxifylline in Management of Oral Submucous Fibrosis

Raju Ram Bishnoi1, Manoj Sharma1, Sharda Bishnoi2, Yash Sharma3

1Postgraduate Student, Department of Oral Medicine and Radiology, Darshan Dental College, Udaipur.
2Reader, Department of Public Health Dentistry, Geetanjali Dental and Research Institute, Udaipur
3MDS, Department of Conservative and Endodontics, Maharaja Ganga Singh Dental College, Rajasthan

Corresponding Author: Raju Ram Bishnoi

ABSTRACT

Aim: To evaluate the efficacy of pentoxifylline in the management of oral submucous fibrosis.
Material and method: This randomized clinical trial was conducted in the Department of Oral Medicine and Radiology, Darshan Dental College, Udaipur from January 2018 to March 2019 consisted of clinical case series of 40 patients distributed equally among study and control group. Pain and burning sensation were recorded using Visual Analogue Scale (VAS) which consists of a straight line with the end points defining extreme limits such as ‘no pain at all’ and ‘pain as bad as it could be.’ Mouth opening was measured by measuring the distance between the centre of incisal edges of maxillary central incisors and mandibular central incisor at maximum opened mouth using VernierCalliper. 3 measurements were recorded consecutively and the average value was calculated and recorded in mm. The patients in either group were followed up after 1st month, 2nd month and 3rd month from commencement of the treatment of the respective therapies.
Results: The difference among 1 month, 2 month, 3 month post-treatment pain assessment and mouth opening score among the study group and the control group is found to be statistically significant
Conclusion: Pentoxifylline can be safer and better alternative treatment for oral submucous fibrosis. Larger sample size and longer treatment duration is necessary in this regard to validate results of the current study.

Keywords: Pentoxifylline, VAS, Oral Submucous Fibrosis

[PDF Full Text]